RESUMO
In the recent years, the role of LOX enzymes in the origin of neoplastic diseases such as colorectal, skin, pancreatic and renal cancers has been confirmed. A new series of 1,3,4-thiadiazole derivatives bearing 2-pyridyl moiety was synthesized and the cytotoxicity of the members of this series was assessed using MTT protocol. Enzyme inhibitory activity of the prepared compounds was also tested against 15-lipoxygenase-1 as a novel target for the discovery of anticancer drugs. PC3, HT29 and SKNMC cell lines were utilized and the obtained results were compared with doxorubicin. Overall, nitro containing derivatives exerted a higher cytotoxic activity against PC3 cell line and methoxylated derivatives showed an acceptable activity against SKNMC cell line. Methoxylated derivatives were also the most potent enzyme inhibitors especially at position ortho of the phenyl residue
RESUMO
This study evaluated the efficacy and safety of metformin on prevention of gestational diabetes mellitus in women with high risk of GDM. Total number of 189 pregnant women aged between 25 to 35, and 10 to 14 weeks pregnancy, admitted to Mirza Koochakkhan Hospital, Tehran in January 2008 - January 2009 entered to this randomized controlled clinical trial. The women had one of the three risk factors; history of GDM, family history of diabetes, or BMI >/- 30 kg/m[2], with normal results in the glucose challenge test [GCT] or the glucose tolerance test [GTT]. Subjects were randomly split to two groups; 63 women [group A] who received metformin [500 mg, twice a day] and 126 women [group B] did not use metformin. Incidence of gestational diabetes was compared between two groups. The incidence of gestational diabetes was significantly different between two groups [%1.4 in group A,%15.4 in group B] [p<0.001]. The study also showed that the insulin requirement was significantly different between two groups after developing GDM [group A%3.6, group B%9.5, p=0.001]. Using Metformin can effectively reduce the incidence of GDM in pregnant women at risk